Corcept Therapeutics (CORT) Other financing activities (2015 - 2026)

Corcept Therapeutics (CORT) has 6 years of Other financing activities data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 47.93% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (up 67.52% YoY), and the FY2025 full-year result was $9.6 million, up 76.24% from the prior year.
• Other financing activities rose to $2.5 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $8.0 million in Q3 2025 to a low of -$3.4 million in Q4 2025.
• A 4-year average of $1.5 million and a median of $1.4 million in 2023 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 522.03% in 2025, while the deepest fall reached 321.08% in 2025.
• Tracing CORT's Other financing activities over 4 years: stood at $886000.0 in 2023, then jumped by 72.91% to $1.5 million in 2024, then slumped by 321.08% to -$3.4 million in 2025, then surged by 174.9% to $2.5 million in 2026.
• Business Quant data shows CORT's Other financing activities at $2.5 million in Q1 2026, -$3.4 million in Q4 2025, and $8.0 million in Q3 2025.